Bloomberg Gadfly columnist Max Nisen says the move may not be much help to either Mr. Paulson, underwater ~$1B with his stake, or the company. Given his track record in pharma, there is scant evidence that he can reprise his colossal win with credit default swaps about a decade ago. Eight of his nin